Algazi A, Tsai K, Bannavong D, et al. Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma supports the rationale for combination therapy. SMR 2017, abstract FC05-3.
Totale overleving met osimertinib bij gereseceerd EGFR-gemuteerd NSCLC
sep 2023 | Longoncologie